Manulife Financial Corp

Manulife Financial Corp (MFC) News & Events

$43.860

+0.772 (+1.76%)At close

MFC News

MFC Events

10/8 10:00

Manulife Appoints Sinead O'Connor as Chief Actuary

Manulife has appointed Sinead O'Connor as Chief Actuary, effective October 12, reporting to Phil Witherington, President and Chief Executive Officer, and joining Manulife's Executive Leadership Team. O'Connor joined Manulife in 2007 and, in addition to her most recent role as Global Head of Inforce Management, she has served as Deputy Chief Actuary, Head of Group Actuarial, US IFRS Chief Actuary, and held leadership roles in Annuities, Long Term Care, and Finance.

9/10 13:30

Manulife Appoints Sarah Chapman as Global Chief Marketing & Customer Experience Officer

Manulife has appointed Sarah Chapman as Global Chief Marketing & Customer Experience Officer, effective January 1, 2027, reporting to Phil Witherington, President and CEO, and joining Manulife's Executive Leadership Team. Chapman will lead Manulife's Global Marketing organization, with responsibility for the company's brand, marketing and enterprise customer experience strategies. Chapman currently serves as CMO for Manulife Canada and leads the company's global Digital, Customer Centricity and Sustainability agendas. Chapman succeeds Karen Leggett, who will retire from Manulife at the end of this year.

8/5 17:31

Manulife Financial Agrees to Biometric Risk Reinsurance with Munich Re

Manulife Financial announced that it has agreed to reinsure biometric risk on a block of long-term care policies with $3.2B of reserves to Munich American Reassurance Company, a subsidiary of Munich Re Group, highlighting the company's continued efforts to reduce the risk profile of its inforce portfolio. The transaction is expected to close in Q4 2026 pending regulatory approvals. Key highlights of the transaction include: Full risk transfer on biometric risk on $3.2B of LTC reserves to Munich Re Life US. Inclusive of our previous LTC reinsurance transactions, upon closing Manulife will have cumulatively reduced LTC morbidity sensitivity by 24%. Similar pricing to prior deals, with a modest negative 5% cede, further validating reserves and assumptions. Transaction largely neutral to capital, with immaterial annual impact to both core earnings and net income attributed to shareholders of about $30M in the first year and reducing over time.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading